Treatments and Prognosis of the Breast Ductal Carcinoma In Situ
Clinical Breast Cancer · 2024-02 · 24 (2) · 122-130.e2
DOI: 10.1016/j.clbc.2023.11.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Breast Cancer, 2024-02. Verfasst von Yaxue Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, PR China. Hauptthemen laut MEDLINE: Carcinoma, Intraductal, Noninfiltrating, Breast Neoplasms, Carcinoma, Ductal, Breast. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
INTRODUCTION: With progress in treatments, breast ductal carcinoma in situ (DCIS) outcomes have substantially improved. However, as various treatment methods are used in different countries and institutions, consensus on the optimal treatment method is lacking. This study aimed to analyze the prognostic factors and provide a reference for optimizing the clinical treatment of DCIS. PATIENTS AND METHODS: This retrospective clinical study collected data from DCIS patients at the Sun Yat-sen University Cancer Center from 2010 to 2017. The Kaplan-Meier method and Cox regression model were used to assess disease-free survival (DFS), overall survival (OS), and local control (LC) rates. RESULTS: Among the 483 included patients, 83.6% (404) underwent mastectomies. The median follow-up time was 101 months. The number of patients undergoing breast-conserving surgery (BCS) with radiotherapy has gradually increased. Axillary lymph node dissection was the main surgery performed from 2010 to 2015, and the proportion of sentinel lymph node biopsies (SLNBs) has increased. LC and DFS rates with BCS without radiotherapy were significantly lower than those with mastectomy (P = .002; P < .001). Additionally, the patients who did not undergo axillary surgery had worse LC and OS rates than those who underwent SLNB (P = .028 and P = .038). Endocrine therapy (ET) or its duration had no significant effect on prognosis. CONCLUSION: In conclusion, BCS without radiotherapy and lack of axillary surgery were independent prognostic factors. We recommend performing BCS with radiotherapy and SLNB more in clinical practice, as well as shortening the ET duration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Oncology, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, PR China.
- Department of Radiation Oncology, Huizhou Central People's Hospital, Huizhou, PR China.
- State Key Laboratory of Oncology, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, PR China. Electronic address: lify@sysucc.org.cn.
Zitieren
APA
Wang, Y., Peng, D., Zhou, X., Hu, W., & Li, F. (2024). Treatments and Prognosis of the Breast Ductal Carcinoma In Situ. Clinical Breast Cancer, 24(2), 122-130.e2. https://doi.org/10.1016/j.clbc.2023.11.001
Vancouver
Wang Y, Peng D, Zhou X, Hu W, Li F. Treatments and Prognosis of the Breast Ductal Carcinoma In Situ. Clinical Breast Cancer. 2024;24(2):122-130.e2. doi:10.1016/j.clbc.2023.11.001
BibTeX
@article{Wang2024,
author = {Wang, Yaxue and Peng, Dingsheng and Zhou, Xinhui and Hu, Wendie and Li, Fengyan},
title = {Treatments and Prognosis of the Breast Ductal Carcinoma In Situ},
journal = {Clinical Breast Cancer},
year = {2024},
volume = {24},
number = {2},
pages = {122--130.e2},
doi = {10.1016/j.clbc.2023.11.001}
}
EUVIMED